For research use only. Not for therapeutic Use.
JAK-IN-21 (Example 4) is a selective and potent JAK inhibitor with IC50s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively[1].
JAK-IN-21 (Example 4) doses not inhibit CYPs and shows good liver microsome stability[1].
JAK-IN-21 (Example 4) shows low bioavailability (F=1.9%)[1].
| Catalog Number | I042904 |
| CAS Number | 2445499-20-5 |
| Synonyms | N-(cyanomethyl)-4-[2-[[1-(cyanomethyl)pyrazol-4-yl]amino]-5-methylpyrimidin-4-yl]benzamide |
| Molecular Formula | C19H16N8O |
| Purity | ≥95% |
| InChI | InChI=1S/C19H16N8O/c1-13-10-23-19(25-16-11-24-27(12-16)9-7-21)26-17(13)14-2-4-15(5-3-14)18(28)22-8-6-20/h2-5,10-12H,8-9H2,1H3,(H,22,28)(H,23,25,26) |
| InChIKey | HTJNRNRPDXBRQY-UHFFFAOYSA-N |
| SMILES | CC1=CN=C(N=C1C2=CC=C(C=C2)C(=O)NCC#N)NC3=CN(N=C3)CC#N |
| Reference | [1]. Zhaokui WAN, et al. Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof. Patent WO2020119819. |
